FHCC Specialty Laboratories

Pharmacokinetics Laboratory Director: Rosa Yeh, PharmD
Medical Director, FHCC Specialty Laboratories: Xueyan Chen, MD, PhD

188 East Blaine Street, PO Box 19023, Suite 250, Seattle, WA 98102-3983
Phone: 206-606-7389 Fax: 206-606-7397 CAP: 8630195 CLIA: 50D2169048

Pharmacokinetics Report for Analysis -- Busulfan

ZZZCARECONNECT, BEAKER **MRN: 5004806087** **DOB:** 11-Jan-1901 **Genetic Sex:** Female
Diagnosis: AML **Location:** Fred Hutch Cancer Center
Ordering Doctor: MASUMI UEDA MD **Referring Doctor:** MASUMI UEDA MD
Dose Administered Date/Time: 14-Mar-2024 09:00 **Dose #:** Test Dose **Dose Administered:** 54.00 mg **# of samples:** 6

Regimen Target Information: **PO Q6**

AUC Target (uMol x Min) 1250 per regimen dose

Observations:

Clearance (ml/min/kg) 2.75
AUC Exposure (uMol x Min) 1000 for Dose #1

Recommended Dose (mg) **54.0** **PO Q6**

% Dose Change 0.0
Starts at Dose # 3
Ends at Dose # 6 [follow-up pending]

AUC Estimated Exposure (uMol x Min) **1250**

Analytical Method: LC-MSD/MSD
Reviewed and Approved By: Sung Choi, PhD, DABCC

Comments:

Part, or all, of the analysis and/or review of this data was performed remotely on digital materials such as digital laboratory results and images. Remote analysis and/or review was completed at P01 and P02.

Figure 1.



Concentration Table

Blood Draw Times (min)	Busulfan Concentration (ng/mL)	Exception Code	Adjusted Concentration (ng/mL)
125	**1350**		
141	**1280**		
160	**1050**		
250	**750**		
309	**380**		
361	**250**		

Exception Handling Codes: 1 = excluded from AUC calculation, 2 = adjusted concentration used in calculations, 3 = other, specify

Note: This test was performed using either gas chromatography with mass selective detection (GC-MSD) or liquid chromatography with mass selective detection (LC-MSD/MSD). This test was developed and its performance characteristics determined by the Fred Hutchinson Cancer Center (FHCC) Pharmacokinetics Laboratory. The U.S. Food and Drug Administration has not approved or cleared this test. This laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) as qualified to perform high complexity clinical laboratory testing.

Disclaimer: The FHCC Pharmacokinetics Laboratory dose recommendations are based on patient-specific measured concentrations. It is the sole responsibility of the prescribing provider to determine therapeutic target exposure and initial and final dosing for each patient. The FHCC will not be liable for any damages resulting from injury to the patient due to clinical management by the provider.